text-only page produced automatically by LIFT Text Transcoder Skip all navigation and go to page contentSkip top navigation and go to directorate navigationSkip top navigation and go to page navigation
National Science Foundation
News
design element
News
News From the Field
For the News Media
Special Reports
Research Overviews
NSF-Wide Investments
Speeches & Lectures
NSF Current Newsletter
Multimedia Gallery
News Archive
News by Research Area
Arctic & Antarctic
Astronomy & Space
Biology
Chemistry & Materials
Computing
Earth & Environment
Education
Engineering
Mathematics
Nanoscience
People & Society
Physics
 

Email this pagePrint this page


Press Release 98-033
Biomaterials Are Transforming Medicine

MIT scientist and engineer describes a new field in an NSF lecture

June 25, 1998

This material is available primarily for archival purposes. Telephone numbers or other contact information may be out of date; please see current contact information at media contacts.

How can doctors deliver drugs in ways less invasive and more controlled than an injection? Robert S. Langer views the question as an engineering design problem. Langer, Germeshausen Professor of Chemical and Biomedical Engineering at MIT, described how researchers are using biomaterials to create engineering solutions to medical problems in a lecture at the National Science Foundation's (NSF) headquarters on June 17.

Langer's lecture, "Biomaterials: From Basic Science and Engineering to Clinical Practice," focused on advances in biomaterials, a field that Langer pioneered. "Historically, materials have found their way into medicine by clinicians," he said. For the first artificial heart, doctors' search for a strong substance with flexibility led them to use polyether urethane, found in girdles. "I thought we could do better," said Langer. After all, "something designed as a lady's girdle might not be the best thing to put in a human body."

Since Langer began his work in 1974, genetic engineering has made possible larger and larger "macromolecule" drugs, such as growth hormones. With the help of NSF grants, Langer found that certain hydrophobic polymers made it possible to deliver macromolecular drugs like albumin into the body and at a controlled rate over a period of time.

Since then, biomaterials have enabled the slow release of ever-larger bioengineered proteins into the body, with release times ranging from one day to more than three years. Products like Lupron Depot permit controlled release of medicines that would normally deteriorate in minutes to be released slowly over four months.

"I'd like to think these are the tip of the iceberg," said Langer. Researchers are also working on ways to deliver growth hormones and methods to provide a constant release of insulin for diabetics. Fortune magazine cited estimates that these new technologies will cause sales in the drug-delivery sector to almost triple, reaching $25 billion by 2006.

For medicines like insulin, research is also exploring methods for administering doses in preprogrammed "pulses," or on demand. Using an oscillating magnetic field, a wristwatch-like device could, for example, release a dose of insulin just before a diabetic's meal. The magnetic field would release the drug by squeezing drug-containing pores at a microscopic level. Trials using such a device on mice are underway.

With Dr. Henry Brem, an oncologist at Johns Hopkins University, Langer explored more focused drug delivery for types of brain cancer. Treatment usually involves chemotherapy, which can have terrible side effects for the liver and other organs. For a more targeted release of the drug BCNU, doctors inserted a dime-sized polymer wafer containing BCNU in the surgical cavity at the tumor. As the polymer eroded, it released the drug over time directly to the tumor without the impediment of the blood-brain barrier. In this study, physicians have used the polymer wafers to treat thousands of brain cancer victims, with significant improvements.

In tissue engineering, cells from a patient can be cultivated on a polymer mesh or "scaffold", allowing regeneration of the cartilage for an ear, for example. Physicians could also apply these techniques to regenerate damaged tendons, sciatic nerve endings and skin tissue.

"We've raised more questions than we've answered," Langer concluded, but biomaterials have already contributed products "that can relieve suffering and prolong life for many people."

-NSF-

Media Contacts
Gregory Lester, NSF, (703) 292-8070, glester@nsf.gov

Program Contacts
Frederick G. Heineken, NSF, (703) 292-7944, fheineke@nsf.gov

The National Science Foundation (NSF) is an independent federal agency that supports fundamental research and education across all fields of science and engineering. In fiscal year (FY) 2014, its budget is $7.2 billion. NSF funds reach all 50 states through grants to nearly 2,000 colleges, universities and other institutions. Each year, NSF receives about 50,000 competitive requests for funding, and makes about 11,500 new funding awards. NSF also awards about $593 million in professional and service contracts yearly.

 Get News Updates by Email 

Useful NSF Web Sites:
NSF Home Page: http://www.nsf.gov
NSF News: http://www.nsf.gov/news/
For the News Media: http://www.nsf.gov/news/newsroom.jsp
Science and Engineering Statistics: http://www.nsf.gov/statistics/
Awards Searches: http://www.nsf.gov/awardsearch/

 

border=0/


Email this pagePrint this page
Back to Top of page